Ascletis' ASC50 Shows Promising Efficacy in Psoriasis Trial…

Event summary

ASC50 achieved a 48.9% placebo-adjusted reduction in PASI score in mild-to-moderate plaque psoriasis patients after a 28-day treatment.
Steady-state elimination half-life of 6.5 days supports potential once-weekly oral dosing.
Placebo-adjusted reduction in PASI score reached 65.9% 15 days after the last dose.
ASC50 demonstrated strong target engagement with elevated plasma IL-17A levels.
Treatment was safe and well-tolerated with only mild adverse events observed.

The big picture

Ascletis' ASC50 represents a potential breakthrough in psoriasis treatment, offering an oral alternative to injectable IL-17A inhibitors. The positive Phase I results position ASC50 as a first-in-class and best-in-class candidate, which could disrupt the current market dominated by antibody therapies. The company's proprietary drug discovery technologies underscore its capability to develop innovative therapeutics in the autoimmune and inflammatory disease space.

What we're watching

Clinical Progression: Whether ASC50 can maintain efficacy and safety in larger, longer-term studies.
Market Differentiation: How ASC50's once-weekly oral dosing compares to existing injectable therapies like secukinumab.
Regulatory Pathway: The pace at which Ascletis advances ASC50 through Phase II and Phase III trials.